Format

Send to

Choose Destination
Intensive Care Med Exp. 2017 Dec;5(1):31. doi: 10.1186/s40635-017-0144-3. Epub 2017 Jul 4.

Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia.

Author information

1
Jamaica Hospital Medical Center, Phase II Building, 8900 Van Wyck Expy Ste 2, Richmond Hill, New York City, NY, 11418, USA.
2
Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany.
3
German Center for Neurodegenerative Diseases (DZNE) e.V., Lynen-Str. 17, 81377, Munich, Germany.
4
Institute of Medical and Polymer Engineering, Department of Mechanical Engineering, Technische Universität München, Munich, Germany.
5
Hepa Wash GmbH, Agnes-Pockels-Bogen 1, 80992, Munich, Germany.
6
Institut für Anästhesiologische Pathophysiologie und Verfahrensentwicklung, Universitätsklinikum Ulm, Helmholtzstr. 8/1, 89081, Ulm, Germany.
7
II Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany.
8
Hepa Wash GmbH, Agnes-Pockels-Bogen 1, 80992, Munich, Germany. bernhard.kreymann@hepawash.com.
9
II Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany. bernhard.kreymann@hepawash.com.

Abstract

BACKGROUND:

Novel extracorporeal procedures are constantly being developed and evaluated for use in patients with sepsis. Preclinical evaluation of such procedures usually requires testing in large animal models. In the present work, the safety and efficacy of a recently developed ADVanced Organ Support (ADVOS) system in a newly developed large animal two-hit model of liver failure combined with endotoxemia were tested.

METHODS:

After establishing the model in more than 50 animals, a randomized study was performed. An inflammatory cholestatic liver injury was initially provoked in pigs. Three days after surgery, endotoxin was gradually administered during 7½ h. Animals were randomized to receive standard medical treatment either with (ADVOS group, n = 5) or without ADVOS (control group, n = 5). The ADVOS treatment was started 2½ h after endotoxemia and continued for 7 h. Survival, cardiovascular, respiratory, renal, liver, coagulation, and cerebral parameters were analyzed.

RESULTS:

Three days after surgery, cholestatic injury resulted in hyperbilirubinemia [5.0 mg/dl (IQR 4.3-5.9 mg/dl)], hyperammonemia [292 μg/dl (IQR 291-296 μg/dl)], leukocytosis [20.2 103/μl (IQR 17.7-21.8 103/μl)], and hyperfibrinogenemia [713 mg/dl (IQR 654-803 mg/dl)]. After endotoxemia, the ADVOS procedure stabilized cardiovascular, respiratory, and renal parameters and eliminated surrogate markers as bilirubin [2.3 (IQR 2.3-3.0) vs. 5.5 (IQR 4.6-5.6) mg/dl, p = 0.001] and creatinine [1.4 (IQR 1.1-1.7) vs. 2.3 (IQR 2.1-3.1) mg/dl, p = 0.01]. Mortality: All animals in the ADVOS group survived, while all animals in the control group expired during the 10-h observation period (p = 0.002). No adverse events related to the procedure were observed.

CONCLUSIONS:

The ADVOS procedure showed a promising safety and efficacy profile and improved survival in a sepsis-like animal model with dysfunction of multiple organs. An amelioration of major organ functions (heart and lung) combined with removal of markers for kidney and liver function was observed.

KEYWORDS:

Albumin dialysis; Animal model; Cholestasis; Endotoxemia; Extracorporeal organ support; Liver failure; Multiple organ failure; Sepsis; Survival; Swine

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center